A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases

Advances in Therapy

Volumn 32, Issue 11, 2015, Pages 983-1028

  Vangeli, Eleni ^a   Bakhshi, Savita ^b   Baker, Anna ^c   Fisher, Abigail ^d   Bucknor, Delaney ^e   Mrowietz, Ulrich ^f   Östör, Andrew J K ^g   Peyrin Biroulet, Laurent ^h   Lacerda, Ana P ⁱ   Weinman, John ^j  

^a LONDON SOUTH BANK UNIVERSITY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Atlantis Health Care   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITÉ DE LORRAINE   (France)

ⁱ ABBVIE INC   (United States)

^j KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Inflammatory bowel disease; Patient adherence; Psoriasis; Psoriatic arthritis; Rheumatology

Indexed keywords

ADALIMUMAB; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ANKYLOSING SPONDYLITIS; DEPRESSION; DOCTOR PATIENT RELATION; HEALTH CARE PERSONNEL; HUMAN; INFLAMMATORY BOWEL DISEASE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PERCEPTION; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SELF CONCEPT; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; TREATMENT REFUSAL; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; INFLAMMATORY BOWEL DISEASES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATORY BOWEL DISEASES; MEDICATION ADHERENCE; PSORIASIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84948575150     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0256-7     Document Type: Review

References (100)

1. Kuek A, Hazleman BL, Östör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgraduate Med J. 2007;83(978):251–60.
2. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337–51.
3. Jackson C, et al. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2009;105(3):525–39.
4. Thorneloe R, et al. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31.
5. Haynes RB, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008:(2):CD000011.
6. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther. 2005;22(4):313–56.
7. World Health Organisation. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.
8. Augustin M, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–74.
9. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Therapeut. 2011;33(7):901–13.
10. Devaux S, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(s3):61–7.
11. Feinberg J. The effect of patient—practitioner interaction on compliance: a review of the literature and application in rheumatoid arthritis. Patient Educ Couns. 1988;11(3):171–87.
12. Kane S. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment pharmacol Therapeut. 2006;23(5):577–85.
13. Hawthorne A, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis–strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Therapeut. 2008;27(12):1157–66.
14. Koncz T, et al. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther. 2010;10(9):1367–78.
15. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010;29(4):260–75.
16. Fiddler HH, Singendonk MMJ, van der Have M, Oldenburg B, van Oijen MGH. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol WJG. 2013;19(27):7.
17. Pasma A, et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. In: Seminars in arthritis and rheumatism. 2013. Elsevier.
18. National Institute for Clinical Excellence. Methods for the development of NICE public health guidance. NICE: London; 2006
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
20. Arturi P, et al. Adherence to treatment in patients with ankylosing spondylitis. Clin Rheumatol. 2013;32(7):1007–15.
21. Beck N, et al. Patients with rheumatoid arthritis at high risk for noncompliance with salicylate treatment regimens. J Rheumatol. 1988;15(7):1081.
22. Borah BJ, et al. Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin. 2009;25(6):1365–77.
23. Brus H, et al. Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient Educ Counseling. 1999;36(1):57–64.
24. Caplan L et al. Health literacy is strongly associated with functional status among rheumatoid arthritis patients: a cross-sectional study. Arthritis Care Res. 2014;66(4):508–14.
25. Chastek B, et al. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther. 2012;29(8):691–7.
26. Cho S-K, et al. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int. 2012;32(12):3851–6.
27. Curkendall S, et al. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Care Res. 2008;59(10):1519–26.
28. de Klerk E, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30(1):44–54.
29. de Thurah A, et al. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int. 2010;30(11):1441–8.
30. Garcia-Gonzalez A, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27(7):883–9.
31. Martínez-Santana V, et al. Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Preference Adherence. 2013;7:719.
32. Müller R, et al. Compliance with treatment of rheumatoid arthritis. Rheumatol Int. 2012;32(10):3131–5.
33. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology. 2005;44(6):762–7.
34. Park D, et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatrics Soc. 1999;47:172–83.
35. Pascual-Ramos V, Contreras-Yáñez I. Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective. BMC Musculoskeletal Disord. 2013;14(1):336.
36. Pascual-Ramos V, et al. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11(1):R26.
37. Quinlan P, et al. The relationship among health literacy, health knowledge, and adherence to treatment in patients with rheumatoid arthritis. HSS Journal®. 2013;9(1):42–9.
38. Saad AA, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11(2):R52.
39. Spruill TM, et al. Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African-American rheumatoid arthritis patients. Ann Rheumatic Dis. 2014;73(1):317–8.
40. Treharne G, Lyons A, Kitas G. Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychol Health Med. 2004;9(3):337–49.
41. Tuncay R, et al. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int. 2007;27(8):743–6.
42. van den Bemt BJ, et al. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36(10):2164–70.
43. Viller F, et al. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol. 1999;26(10):2114–22.
44. Waimann CA, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheumat. 2013;65(6):1421–9.
45. Wong M, Mulherin D. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskeletal Care. 2007;5(3):148–59.
46. Bermejo F, et al. Factors that modify therapy adherence in patients with inflammatory bowel disease. J Crohn’s Colitis. 2010;4(4):422–6.
47. Bernal I, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Digestive Dis Sci. 2006;51(12):2165–9.
48. Billioud V, et al. Adherence to adalimumab therapy in Crohn’s disease: a French multicenter experience. Inflamm Bowel Dis. 2011;17(1):152–9.
49. Bokemeyer B, et al. Adherence to thiopurine treatment in out-patients with Crohn’s disease. Aliment Pharmacol Therapeut. 2007;26(2):217–25.
50. Carter CT, Waters HC, Smith DB. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease. Patient Preference Adherence. 2012;6:417.
51. Červený P, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflammatory Bowel Dis. 2007;13(10):1244–9.
52. Cerveny P, et al. Non-adherence to treatment in inflammatory bowel disease in Czech Republic. J Crohn’s Colitis. 2007;1(2):77–81.
53. D’Inca R, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Therapeut. 2008;27(2):166–72.
54. Ediger JP, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102(7):1417–26.
55. Goodhand J, et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Therapeut. 2013;38(9):1097–108.
56. Horváth G, et al. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease? Scand J Gastroenterol. 2012;47(11):1298–303.
57. Horne R, et al. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(6):837–44.
58. Kamperidis N, et al. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;54(5):685–9.
59. Kane SV, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56(12):3463–70.
60. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Therapy. 2009;26(10):936–46.
61. Kane SV, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96(10):2929–33.
62. Lachaine J, et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol. 2013;13(1):23.
63. Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol WJG. 2009;15(34):4234.
64. Linn AJ, et al. May you never forget what is worth remembering: the relation between recall of medical information and medication adherence in patients with inflammatory bowel disease. J Crohn’s Colitis. 2013;7(11):e543–50.
65. Mantzaris GJ, et al. How adherent to treatment with azathioprine are patients with Crohn’s disease in long-term remission? Inflam Bowel Dis. 2007;13(4):446–50.
66. Mitra D, et al. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012;12(1):132.
67. Moradkhani A, et al. Disease-specific knowledge, coping, and adherence in patients with inflammatory bowel disease. Digest Dis Sci. 2011;56(10):2972–7.
68. Moshkovska T, et al. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Aliment Pharmacol Ther. 2009;30(11–12):1118–27.
69. Nahon S, et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis. 2011;17(6):1270–6.
70. Nahon S, et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(11):2086–91.
71. Nguyen GC, et al. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(8):1233–9.
72. Nigro G, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol. 2001;32(1):66–8.
73. Robinson A, et al. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Therapeut. 2013;38(5):531–8.
74. Román San. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig. 2005;97(4):249–57.
75. Selinger CP, et al. modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2199–206.
76. Selinger CP, Kemp A, Leong RW. Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. Expert Rev Gastroenterol Hepatol. 2014;1:6.
77. Sewitch MJ, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98(7):1535–44.
78. Shale M, Riley S. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Therapeut. 2003;18(2):191–8.
79. Taft TH, et al. Impact of perceived stigma on inflammatory bowel disease patient outcomes. Inflamm Bowel Dis. 2009;15(8):1224–32.
80. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. J Can Gastroenterol. 2005;19(4):235–44.
81. Yen L, et al. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharmacy. 2012;18(9):701.
82. Altobelli E, et al. Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features. J Eur Acad Dermatol Venereol. 2012;26(8):976–82.
83. Bhosle MJ, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatol Treat. 2006;17(5):294–301.
84. Chan SA, et al. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatol Treatment. 2013;24(1):64–9.
85. Chastek B, et al. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24(1):25–33.
86. Clemmensen A, et al. Responses to ustekinumab in the anti-TNF agent-naïve versus anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2011;25(9):1037–40.
87. Esposito M, et al. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–72.
88. Gniadecki R, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–6.
89. Gokdemir G, Arı S, Köşlü A. Adherence to treatment in patients with psoriasis vulgaris: turkish experience. J Eur Acad Dermatol Venereology. 2008;22(3):330–5.
90. Richards HL, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581–3.
91. Umezawa Y, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40(12):1008–13.
92. Zaghloul S, Goodfield M, Jeremey D. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–14.
93. De Korte J, et al. Quality of life in patients with psoriasis: a systematic literature review.J Investigative Dermatol Symposium Proc. 2004. Nature Publishing Group.
94. Coleman CI, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–39.
95. Saini SD, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22–33.
96. Kardas P, et al. 3 report on the determinants of patient non-adherence with short-term therapies and treatments for chronic diseases in Europe. Ascertaining barriers for compliance: policies for safe, effective and cost-effective use of medicines in Europe Final Report of the ABC Project (Deliverable 7.1), 2012. p. 40.
97. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.
98. Arnett PA, Higginson CI, Voss WD, Bender WI, Wurst JM, Tippin JM. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology. 1999;13(4):11.
99. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Services Res. 2012;12(1):98.
100. Van den Bemt B, et al. Making the rheumatologist aware of patients’ non-adherence does not improve medication adherence in patients with rheumatoid arthritis. Scand J Rheumatol. 2011;40(3):192–6.